Ildong Pharmaceutical Co., Ltd.

249420.KS · Korea Exchange · KRW

12.760,00KRW

+510,00 (+4,16 %)Stand 10. Nov., 6:30

Vortag 12.250,00

Kennzahlen

Eröffnung
12.390,00
Vortag
12.250,00
Tagesspanne
12.390,00 – 12.840,00
52 Wochen
11.250,00 – 45.050,00
Volumen
91.267
Ø Volumen
247.523
Börsenwert
402,04 Mrd. KRW
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
0,8
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Ildong Pharmaceutical Co., Ltd., established in 1941 and headquartered in Seoul, South Korea, is a company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its extensive portfolio includes various medications such as anti-diarrheal agents, antibiotics, antifungals, antivirals, antihistamines, anticancer drugs, NSAIDs, and pain relievers, along with essential vitamins, minerals, and nutritional supplements. The company also produces treatments for numerous bodily systems, including cardiovascular, central nervous, dental, endocrine, gastrointestinal, respiratory, topical, and urogenital health, as well as those for blood circulation. Beyond pharmaceuticals, Ildong offers raw material drugs, health foods, cosmetics, and specialized medical devices, such as scar treatment products. Their range also extends to unique treatments for conditions like osteoarthritis, wound care, artificial tears, and feminine hygiene products. In addition to its product offerings, the company manages licenses and provides contract manufacturing services. With a global reach, Ildong Pharmaceutical exports its products to approximately 20 countries. Furthermore, the company has entered into a strategic collaboration with Evotec SE, leveraging Evotec's INDiGO platform to accelerate the development of its proprietary projects.

CEO
Yun Paul Woongsup
Mitarbeitende
1.104
Hauptsitz
Seoul, SL, KR
Sektor
Healthcare
Branche
Drug Manufacturers - Specialty & Generic
Börsengang
31. Aug. 2016
Website
ildong.com

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.